- Home
- SAVA vs CPHC Comparison
SAVA vs CPHC Comparison
Compare SAVA & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CPHC
- Stock Information
- Founded
- SAVA 1998
- CPHC 1994
- Country
- SAVA United States
- CPHC United States
- Employees
- SAVA N/A
- CPHC N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- SAVA Health Care
- CPHC Consumer Discretionary
- Exchange
- SAVA Nasdaq
- CPHC Nasdaq
- Market Cap
- SAVA 102.4M
- CPHC 92.5M
- IPO Year
- SAVA N/A
- CPHC 1994
- Fundamental
- Price
- SAVA $2.34
- CPHC $16.89
- Analyst Decision
- SAVA Hold
- CPHC
- Analyst Count
- SAVA 1
- CPHC 0
- Target Price
- SAVA $2.00
- CPHC N/A
- AVG Volume (30 Days)
- SAVA 867.7K
- CPHC 2.0K
- Earning Date
- SAVA 08-14-2025
- CPHC 08-07-2025
- Dividend Yield
- SAVA N/A
- CPHC 1.66%
- EPS Growth
- SAVA N/A
- CPHC N/A
- EPS
- SAVA N/A
- CPHC 0.03
- Revenue
- SAVA N/A
- CPHC $60,069,270.00
- Revenue This Year
- SAVA N/A
- CPHC N/A
- Revenue Next Year
- SAVA N/A
- CPHC N/A
- P/E Ratio
- SAVA N/A
- CPHC $573.50
- Revenue Growth
- SAVA N/A
- CPHC N/A
- 52 Week Low
- SAVA $1.15
- CPHC $16.15
- 52 Week High
- SAVA $33.98
- CPHC $22.93
- Technical
- Relative Strength Index (RSI)
- SAVA 54.06
- CPHC 35.64
- Support Level
- SAVA $2.20
- CPHC $16.93
- Resistance Level
- SAVA $2.43
- CPHC $17.95
- Average True Range (ATR)
- SAVA 0.17
- CPHC 0.26
- MACD
- SAVA -0.00
- CPHC -0.13
- Stochastic Oscillator
- SAVA 60.42
- CPHC 29.74
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.